The abnormal involuntary movement scale (AIMS) and tardive dyskinesia in persons with developmental disability: The benefit of videotaped exams

Mental Health Aspects of Developmental Disabilities

Volumn 8, Issue 3, 2005, Pages 94-99

  Ruedrich, Stephen ^a,c   Diana, Linda ^b   Rossvanes, Christopher F ^b   Toliver, James ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Youngstown Developmental Center   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Abnormal involuntary movement scale (AIMS); Antipsychotic medications; Developmental disability; Intellectual disability; Mental retardation; Movement disorders; Neuroleptic induced tardive dyskinesia; Psychiatric disorder; Rating scales; Videotaping

Indexed keywords

ALPHA TOCOPHEROL; BENZATROPINE; CHLORPROMAZINE; ESCITALOPRAM; FLUPHENAZINE; FLUVOXAMINE; LOXAPINE; NEUROLEPTIC AGENT; PERPHENAZINE; PIPERACETAZINE; PYRIDOXINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; CASE REPORT; DEVELOPMENTAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; RATING SCALE; RELIABILITY; REVIEW; SCREENING; TARDIVE DYSKINESIA; VIDEOTAPE;

EID: 24944570117     PISSN: 10573291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1994.
2. American Psychiatric Association. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association Press, 1992.
3. American Psychiatric Association. Task Force Report 18: Tardive Dyskinesia. Washington, DC: American Psychiatric Association, 1979.
4. Barnes TR, Trauer T. Reliability and validity of a tardive dyskinesia videotape rating technique. Br J Psychiatry 1982;140:508-515.
5. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;6:25-28.
6. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second- generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425.
7. Dean CE, Russell JM, Kuskowski MA, et al. Clinical rating scales and instruments: How do they compare in assessing abnormal, involuntary movements? J Clin Psychopharmacol 2004;24:298-304.
8. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003;53:1142-1145.
9. Fann WE, Stafford JR, Malone RL, et al. Clinical research techniques in tardive dyskinesia. Am J Psychiatry 1977;134:759-762.
10. Gardos G, Cole JO, La Brie R. The assessment of tardive dyskinesia. Arch Gen Psychiatry 1977;34:1206-1212.
11. Gerlach J, Korsgaard S, Clemmesen P, et al. The St. Hans Rating Scale for extrapyramidal syndromes: Reliability and validity. Acta Psychiatr Scand 1993;87:244-252.
12. Granger DA, Yurkunski JM, Miller NH, et al. Systematic dyskinesia examination of profoundly mentally retarded persons: Cooperation and assessment. Am J Ment Defic 1987;92:155-160.
13. Gualtieri CT, Schroeder SR, Hicks RE, Quade D. Tardive dyskinesia in young mentally retarded individuals. Arch Gen Psychiatry 1986;43:335-340.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology (rev. ed.). Washington, DC: U.S. Government Printing Office, 1976.
15. Kalachnik JE, Leventhal BL, Janes DH, Sovner R, Kastner TA, Walsh K, Weisblatt SA, Klitzke MG. Guidelines for the use of psychotropic medication. In: Reiss S, Aman M (eds), Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University Press, 1998:45-72.
16. Kalachnik JE, Slaw KM. Applied Tardive Dyskinesia Monitoring, Second Edition, 1991.
17. Kalachnik JE, Sprague RL, Slaw KM. Training clinical personnel to assess for tardive dyskinesia. Prog Neuropsychopharmacol Bio Psychiatry 1988;12:749-762.
18. Karstaedt PJ, Pincus JH, Coughlin SS. Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report. Arch Neurol 1991;48:402-405.
19. Lane RD, Glazer WM, Hansen TE, et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985;173:353-357.
20. Lohr JB, Caligiuri MP. Quantitative instrumental measurement of tardive dyskinesia: A review. Neuropsychopharmacology 1992;6:231-239.
21. Mackenzie CF, Hu PF, Horst RL An audio-video system for automated data acquisition in the clinical environment. LOTAS Group. J Clin Monit 1995;11:335-341.
22. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988;39:1172-1177.
23. Munetz MR, Benjamin S. Who should perform the AIMS examination? Hosp Community Psychiatry 1990;41:912-915.
24. Nilsson FM, Hansen BL, Buchel C, et al. Digital movement analysis, a new objective method of measuring tardive dyskinesia and drug-induced parkinsonian tremor: Acceptability, reliability, and validity. Eur Arch Psychiatry Clin Neurosci 1996; 246:71-77.
25. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979;64:171-179.
26. Shay J, Sanchez LE, Cueva JE, et al. Neuroleptic-related dyskinesias and stereotypies in autistic children: Videotaped ratings. Psychopharmacol Bull 1993;29:359-363.
27. Sprague RL, Kalachnik JE. Reliability, validity, and a total score cutoff for the dyskinesia identification system: Condensed user scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacol Bull 1991;27:51-58.
28. Sprague RL, Kalachnik JE, Breuning SE, et al. The dyskinesia identification system-Coldwater (DIS-Co): A tardive dyskinesia rating scale for the developmentally disabled. Psychopharmacol Bull 1984;20:328-338.
29. Tracy K, Adler LA, Rotrosen J, et al. Inter-rater reliability issues in multi-center trials, Part I: Theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study # 394. Psychopharmacol Bull 1997;33:53-57.
30. Wilson JG, Lott RS, Tsai L. Side effects: Recognition and management. In: Reiss S, Aman M (eds), Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: Ohio State University Press, 1998:95-114.